All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

ISAL 2019 | Inhibitors of IDH1 and IDH2 for targeted therapy in acute myeloid leukemia 

Mar 20, 2019

On February 25, 2019, Courtney DiNardo from The University of Texas MD Anderson Cancer Center, Houston, TX, presented at the Acute Leukemias XVII Biology and Treatment Strategies biennial symposium, in Munich, Germany on isocitrate dehydrogenase (IDH) type 1 (IDH1) and IDH type 2 (IDH2) inhibitors in the treatment of acute myeloid leukemia (AML). Dr. DiNardo began by discussing the biology of IDH mutations, moving on to discuss how these have been utilized as therapeutic targets in AML and showing the data that led to the clinical adoption of the IDH inhibitors enasidenib and ivosidenib. The presentation concluded with a summary of ongoing trials of these inhibitors in combination therapies.1

IDH mutations – biology

Whilst IDH mutations are not the most commonly occurring in AML, approximately 20% of patients have mutant IDH (mIDH) genes with approximately 8% affecting IDH1 and 12% in IDH2. These mutations are early events, with 20% of IDH1 and 35% of IDH2 occurring at diagnosis. However, these can also be acquired during progression from myelodysplastic syndrome or myeloproliferative neoplasms to AML in 10–15% and 20–25% of cases, respectively.

At a cellular level, IDH1 (in the cytoplasm) and IDH2 (in the mitochondria) usually act to metabolize the reaction of isocitrate to α-ketoglutarate (α-KG). When these genes are mutated, α-KG cannot breakdown D-2-hydroxyglutarate (2-HG), an oncometabolite, causing it to accumulate and inhibit α-KG-dependent dioxygenases. This leads to impaired differentiation, epigenetic changes, and metabolic dysregulation.

Targeting IDH1 and IDH2

Currently, there are two IDH inhibitors approved for the treatment of AML by the U.S. Food and Drug Administration (FDA). These are AG-120 (ivosidenib, TIBSOVO®) for mIDH1 and AG-221 (enasidenib, IDHIFA®) for mIDH2.2,3 Others under investigation include IDH305 for mIDH1 and AG-881 for both IDH1 and IDH2 inhibition.

Bin Fan et al. identified that ivosidenib effectively inhibits 2-HG in patients with mIDH1 AML with a reduction to normal plasma 2-HG levels in the majority of patients, at all doses. The study also supported once-daily oral dosing (QD).4

Enasidenib for mIDH2

In a first-in-human phase I/II study (NCT01915498), patients with advanced myeloid malignancies with IDH2 mutations were enrolled into the dose escalation phase. Patients were given cumulative daily doses of 50–650 mg of enasidenib in continuous 28-day cycles. This identified the optimal dose of 100 mg, daily, with no maximum tolerated dose (MTD) reached. This study then moved into the expansion phase, recruiting patients predominantly with relapsed/refractory (R/R) mIDH2 AML.5 The updated results from this study were presented by Dr. DiNardo and are shown in Table 1 below, in patients with R/R AML.6

Table 1: Efficacy of enasidenib in R/R AML


Enasidenib, 100 mg/day

(n = 214)

Overall response rate (ORR)

83 (38.8%)

Complete remission (CR) + CR with incomplete hematologic recovery/CR with incomplete platelet recovery (CRi/CRp)

62 (29%)

Best response:



Partial remission (PR)

Morphologic leukemia-free state (MLFS)

Stable disease (SD)

Progressive disease (PD)

Not evaluable (NE)


42 (19.6%)

20 (9.3%)

9 (4.2%)

12 (5.6%)

98 (45.8%)

19 (8.9%)

3 (1.4%)

Overall survival (OS) (n = 280)

Median OS

Median OS with CR (n = 42)

Median OS with non-CR response

Median OS with NR


8.8 months (7.7–9.6)

22.9 months

10.6 months

5.6 months

In a paper by Michael D. Amatangelo et al. the impact of co-occurring mutations on response to treatment with enasidenib was investigated. In this study, fewer co-occurring mutations were observed in patients achieving a response (≥PR or CR). The ORR of patients with a low mutational burden (≤ 3 co-occurring mutations) (n = 27) was 70.4% compared to 21.9% in patients with a high mutational burden (≥ 6 co-occurring mutations) (n = 32). Additionally, NRAS mutations were found to be significantly correlated with CR rates (P = 0.0114).7

Ivosidenib for mIDH1

In the first-in-human phase I study (NCT02074839) of ivosidenib in patients with mIDH1, patients with advanced hematologic malignancies with mIDH were recruited for a dose escalation phase. Patients were treated with 100 mg twice daily (BID) or 300 mg, 500 mg, 800 mg or 1200 mg QD. The MTD was not reached. The optimal dose, however, was found to be 500 mg QD. An expansion cohort of patients with mIDH1 R/R AML, untreated AML or non-AML mIDH1 advanced hematologic malignancies were treated with this dose.8

Table 2 shows the results presented by Dr. DiNardo in patients with R/R AML with a median of 2 prior therapies.1

Table 2: Efficacy of ivosidenib in R/R AML


Ivosidenib, 500 mg/day

(n = 179)

Overall response rate (ORR) (95% CI)

75 (41.9%, 34.6–49.5)

CR + CR with partial hematologic recovery (CRh) (95% CI)

57 (31.8%, 25.1–39.2)

Best response:






Not assessed (NA)


43 (24.0%)

21 (11.7%)

11 (6.1%)

68 (38.0%)

15 (8.4%)

21 (11.7%)


Median OS

Median OS with CR/CRh

Median OS with non-CR/CRh responders

Median OS in non-responders


9 months (7–10)

18.8 months

9 months

5 months

Further studies evaluating the impact of the depth of response have been conducted. These include an investigation by Daniel A. Pollea et al. where patients treated with ivosidenib who had deeper clearance of IDH1, as detected by digital polymerase chain reaction, had an improved OS. In this study, this was not statistically significant due to the small sample size 9

Mechanisms of relapse in patients with mIDH10

In a study by Lynn Quek et al. clonal heterogeneity was examined in patients with mIDH2 AML treated with enasidenib. At relapse, in patients who had acquired resistance to enasidenib, no second-site IDH2 mutations were detected. However, investigators observed seven patterns of clonal evolution/selection indicating these were the main mechanisms of acquired resistance.

Additionally, by measuring 2-HG levels in sixteen patients at diagnosis and relapse, it was observed that fourteen of these remained suppressed between best response and relapse. In most patients, therefore, relapsed clones did not appear to be dependent upon mIDH2 with enasidenib remaining on-target. In the two patients whose 2-HG levels increased, mutations in IDH1 were observed, which, prior to treatment, were not detectable using next-generation sequencing. This indicated IDH1 mutations were present in mIDH2 clones with isoform switching another relapse mechanism.

Combination treatment with IDH inhibitors

Another regimen being investigated is using IDH inhibitors in combination treatments. Current studies utilizing these strategies include ivosidenib/enasidenib with azacitidine or with standard chemotherapy, such as cytarabine and daunorubicin or idarubicin.

Ivosidenib or enasidenib in combination with azacitidine (AZA):1,11,12

  • Adult patients with newly diagnosed AML who are ineligible for chemotherapy
  • Phase Ib dose-finding and expansion and phase II randomized trial design:
    • mIDH1: ivosidenib arm
      • Phase Ib: dose-finding phase (n = 7): ivosidenib (500 mg QD) + AZA
      • Phase Ib: expansion phase (n = 16): ivosidenib (500 mg QD) + AZA
    • mIDH2: enasidenib arm
      • Phase Ib: dose-finding phase (3+3)
        • Enasidenib: 100 mg QD + AZA
        • Enasidenib: 200 mg QD + AZA
      • Phase II: randomized study (n = 99)
        • Enasidenib: 100 mg QD + AZA (n = 66)
        • AZA monotherapy (n = 33)
    • AZA (administered subcutaneously): 75 mg/m2/day x 7 days per 28 day cycle (all phases)
    • Phase Ib:
      • Primary endpoint: recommended combination dose and safety
      • Secondary endpoints: ORR, CR rate, mIDH variant allele frequency
    • Phase II:
      • Primary endpoint: ORR
      • Secondary endpoints: safety, event-free survival (EFS) and OS

Dr. DiNardo presented the results from this study, as shown in Table 3 below.

Table 3: Results of phase Ib studies: the efficacy of IDH inhibitor combination treatments


Ivosidenib + AZA

(n = 23)

Enasidenib + AZA

(n = 6)


18 (78%)

4 (67%)


13 (57%)

3 (50%)


3 (13%)

0 (0%)


0 (0%)

0 (0%)


2 (9%)

1 (17%)

Median time to first response

1.8 months (0.7–3.8)


Median time to best response

3.6 months (0.8–6.7)


Median duration of response

Not reached


The ivosidenib cohort has now been progressed into a multicenter, double-blind, placebo-controlled, randomized, phase III study investigating invosidenib versus placebo with AZA in previously untreated patients with AML with IDH1 mutations (AGILE, NCT03173248). The enasidenib phase II study is still currently enrolling.

Ivosidenib and enasidenib with standard chemotherapy:1,13

  • Patients with AML who are fit for intensive chemotherapy at the time of diagnosis
  • Open-label, multicenter, phase I study (NCT02632708)
  • Ivosidenib or enasidenib with cytarabine (ARA-C) and daunorubicin (DNR) or idarubicin (IDR)
    • ARA-C dose: 200 mg/m2/day x 7 days
    • DNR dose: 60 mg/m2/day x 3 days
    • IDR dose: 12 mg/m2/day x 3 days
  • Induction (1–2 cycles):
    • mIDH1: ivosidenib (500 mg) + ARA-C + DNR or IDR
    • mIDH2: enasidenib (100 mg) + ARA-C + DNR or IDR
  • Consolidation after CR/CRi/CRp (≤4 cycles):
    • mIDH1: ivosidenib (500 mg) + ARA-C
    • mIDH2: enasidenib (100 mg) + ARA-C
  • Maintenance: after CR/CRi/CRp (up to 2 years from day 1 of induction)
    • mIDH1: ivosidenib (500 mg) daily
    • mIDH2: enasidenib (100 mg) daily

All data given as ivosidenib versus enasidenib

  • Patient characteristics:
    • Patient numbers: 60 vs 93
    • Median age: 62.5 (24–76) vs 63 (27–77) years
    • De novo AML: 42 (70%) vs 59 (63%)
    • Poor cytogenetics: 20 (33%) vs 29 (31%)
    • Co-occurring mutations:
      • mIDH1: DNMT3A, NPM1, ASXL1 and BCOR
      • mIDH2 group: DNMT3A, SRSF2, ASXL1 and RUNX1

Dr. DiNardo presented the results from this study, as shown in Table 4 below.

Table 4: Results of phase I study of induction + ivosidenib or enasidenib. Data cut-off 01 Aug 2018.


Ivosidenib + chemotherapy

(n = 49)

Enasidenib + chemotherapy

(n = 89)

CR + CRi/CRp





Treatment failure

39 (80%)

35 (71%)

4 (8%)

3 (6%)

1 (2%)

6 (12%)

64 (72%)

50 (56%)

14 (16%)

11 (12%)

1 (1%)

13 (15%)

Measurable residual disease (MRD)-negative (CR/CRi/CRp best response group)

15 (88%) (n = 17)

9 (45%) (n = 20)

Median follow-up (months)



Estimated 12-month OS after induction day 1 (%)



Median OS (months)

Not estimable

Not estimable

Future Studies

A phase III study, HOVON 150/ AMLSG 29-18, stratifying patients by mIDH status aims to recruit approximately a thousand patients with AML who are eligible for intensive chemotherapy at the end of 2018. The study will determine the efficacy of enasidenib or ivosidenib with chemotherapy versus placebo treatment. The induction treatment is two cycles of 7+3 and enasidenib (mIDH2) or ivosidenib (mIDH1) versus 7+3 and placebo. This is followed by consolidation chemotherapy (1 or 3 cycles) and allo- or auto-hematopoeitic stem cell transplant (HSCT). The maintenance phase will be enasidenib (mIDH2) or ivosidenib (mIDH1) versus placebo.14

A phase Ib/II study investigating the combination of ivosidenib and venetoclax with and without AZA. The primary endpoints of the study will be safety, tolerability, MTD and recommended phase II dose of ivosidenib + venetoclax +/- AZA. Ivosidenib (500 mg QD) will be administered continuously from day 15 with the venetoclax dose as per protocol, on days 1–14 per 28-day cycle and AZA (75 mg/m2 on days 1–7) as per protocol. In the phase I cohort, dosing will be:

  • Starting dose (0): 400 mg venetoclax + ivosidenib
  • Target dose (+1): 800 mg venetoclax + ivosidenib
  • Target dose (+2): 400 mg venetoclax + ivosidenib + AZA


Patients with IDH1 or IDH2 mutant R/R AML can be treated with the oral agents, ivosidenib, and enasidenib, which are safe and effective as single-agent therapy. However, it is expected that combining these with other regimens, such as 7+3 and AZA, will improve responses and durability. Studies combining these with targeted therapies, such as FLT3i, will also be undertaken, or are ongoing, to investigate any additional benefit.

  1. DiNardo C.D. IDH1 and IDH2 Inhibitors. 2019 Feb 25. ACUTE LEUKEMIAS XVII Biology and Treatment Strategies Meeting, Munich, DE
  2. U.S. Food & Drug Administration. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. [Accessed 2019 March 14]
  3. U.S. Food & Drug Administration. FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia. [Accessed 2019 March 14]
  4. Fan B. et al. Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies. Blood. 2015 126:1310.
  5. Stein E.M., DiNardo C.D. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10. DOI: 10.1182/blood-2017-04-779405
  6. Stein E.M. et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14. DOI: 10.1182/blood-2018-08-869008
  7. Amatangelo M.D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017 Jun 06. DOI: 10.1182/blood-2017-04-779447
  8. DiNardo C.D. et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. New Eng J Med. 2018 Jun 21. DOI: 10.1056/NEJMoa1716984
  9. Pollyea D.A. et al. Ivosidenib (AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia: results of a phase I study. Abstract #S1560. 23rd Congress of the European Hematology Association; 2018 June 14–17; Stockholm, SE
  10. Quek L., David M.D. et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018 Jul 16. DOI: 10.1038/s41591-018-0115-6
  11. DiNardo C.D. et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). Abstract #S1562. 23rd Congress of the European Hematology Association; 2018 June 14–17; Stockholm, SE
  12. DiNardo C.D. et al. Poster presented during ISAL 2019. ACUTE LEUKEMIAS XVII Biology and Treatment Strategies Meeting, Munich, DE
  13. Stein E.M. et al. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. Abstract #560. ASH 60th Annual Meeting and Exposition, San Diego, CA.
  14. HOVON: Clinical picture: AML (acute myeloid leukemia) Trial: HOVON 150 AML. [accessed 2019 March 15]